Source comparison
Plasma Half-Life vs Biological Activity Window
Thymosin Alpha-1 exhibits a two-phase clearance profile. The alpha phase. Distribution into tissues from plasma. Occurs within 30–60 minutes post-injection. The beta phase. Elimination from the body. Follows a half-life of approximately 2–3 hours, meaning four
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1 exhibits a two-phase clearance profile. The alpha phase. Distribution into tissues from plasma. Occurs within 30–60 minutes post-injection. The beta phase. Elimination from the body. Follows a half-life of approximately 2–3 hours, meaning four half-lives (the standard pharmacological threshold for 94% clearance) occur within 8–12 hours. At that point, the peptide itself is no longer measurable in serum at standard detection thresholds.
- What persists is the immune cascade. Thymosin Alpha-1 binds to TLR9 receptors on dendritic cells and macrophages, triggering nuclear translocation of transcription factors that upregulate cytokine production. IL-2 and IL-7. The primary cytokines induced by Thymosin Alpha-1. Have their own half-lives (75–90 minutes for IL-2, 4–6 hours for IL-7) but initiate T-cell proliferation and differentiation cycles that continue for 48–72 hours. This is the biological activity window, and it's what determines dosing frequency in research protocols.
- A 2019 study published in Immunopharmacology and Immunotoxicology tracked CD4+ and CD8+ T-cell counts in subjects receiving subcutaneous Thymosin Alpha-1. Peak T-cell activation occurred 24–36 hours post-injection. Long after plasma Thymosin Alpha-1 had cleared. The implication: researchers dosing daily are overlapping immune cascades unnecessarily. Twice-weekly protocols (Monday/Thursday or similar spacing) align dosing with the natural resolution of the prior cascade.